Hologic(US:HOLX) ZACKS·2025-10-16 22:46Core Viewpoint - Hologic's stock performance has been mixed, with a recent increase but a decline over the past month, and upcoming earnings are anticipated to show growth in earnings per share and revenue [1][2][3]. Company Performance - Hologic closed at $68.50, reflecting a +2.24% change from the previous day, outperforming the S&P 500, which fell by 0.63% [1]. - Over the last month, Hologic's shares decreased by 1.76%, while the Medical sector gained 3.09% and the S&P 500 increased by 0.92% [1]. Upcoming Earnings - The earnings report is expected on November 3, 2025, with projected earnings of $1.1 per share, indicating a year-over-year growth of 8.91% [2]. - The Zacks Consensus Estimate for revenue is $1.03 billion, representing a 4.67% increase from the previous year [2]. Full Year Estimates - For the full year, analysts expect earnings of $4.24 per share and revenue of $4.08 billion, reflecting changes of +3.92% and 0% respectively from last year [3]. - Recent changes in analyst estimates are crucial as they often indicate shifts in near-term business trends [3]. Analyst Ratings - Hologic currently holds a Zacks Rank of 4 (Sell), with a recent 0.11% decrease in the Zacks Consensus EPS estimate over the last 30 days [5]. - The Zacks Rank system has a strong track record, with stocks rated 1 producing an average annual return of +25% since 1988 [5]. Valuation Metrics - Hologic has a Forward P/E ratio of 14.96, which is lower than the industry average of 23.97 [6]. - The company has a PEG ratio of 2.3, compared to the industry average PEG ratio of 2.54 [6]. Industry Context - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 89, placing it in the top 37% of over 250 industries [7]. - Strong industry rankings correlate with stock performance, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7].